Pharmadrug (TSE:PHRX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
PharmaDrug is celebrating a significant advancement as its majority-owned subsidiary Sairiyo Therapeutics receives approval for a Phase 1 clinical trial in Australia. The trial will investigate the patented, reformulated oral drug PD-001, with potential applications in treating cancer and infectious diseases. This milestone follows years of research and will be instrumental in seeking FDA approval for further trials in the US.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.